6-Sulfatoxymelatonin as a predictor of clinical outcome in depressive patients

Human Psychopharmacology

Volumn 26, Issue 3, 2011, Pages 252-257

  Hidalgo, Maria Paz Loayza ^a,b   Caumo, Wolnei ^a   Dantas, Giovana ^a   Franco, Daiane Gil ^c   Da Silva Torres, Iraci Lucena ^a   Pezzi, Julio ^a   Elisabetsky, Elaine ^a   Detanico, Bernardo Carraro ^a   Piato, Ângelo ^a   Markus, Regina P ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

6 sulfatoxymelatonin (aMT6s); Depression; Melatonin; Tricyclic antidepressant

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; NORTRIPTYLINE;

6 SULFATOXYMELATONIN URINE LEVEL; ADULT; ARTICLE; DEPRESSION; DRUG DOSE INCREASE; FEMALE; HAMILTON SCALE; HORMONE URINE LEVEL; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MELATONIN; MIDDLE AGED; NORTRIPTYLINE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051793542     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1204     Document Type: Article

References (33)

1. Avellar MC, Kobashi YL, Markus RP. 1990. Age-related changes in neuronal uptake of noradrenaline. Naunyn Schmiedebergs Arch Pharmacol 341: 295-300. (Pubitemid 20137882)
2. Avellar MC, Markus RP. 1993. Age-related changes in norepinephrine release and its modulation by presynaptic alpha-2 adrenoceptors in the rat vas deferens. J Pharmacol Exp Ther 267: 38-44. (Pubitemid 23324986)
3. Avissar S, Schreiber G. 2006. The involvement of G proteins and regulators of receptor-G protein coupling in pathophysiology, diagnosis and treatment of mood disorders. Clin Chim Acta 336: 37-47. (Pubitemid 43330965)
4. Briley M, Moret C. 2010. Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors. Neuropsychiatr Dis Treat 6: 647-655.
5. Camozzato AL, Hidalgo MP, Souza S, Chaves ML. 2007. Association among items from the self-report version of the Hamilton Depression Scale (Carroll Rating Scale) and respondents' sex. Psychol Rep 101(1): 291-301.
6. Carvalho LA, Gorenstein C, Moreno RA, Markus RP. 2006. Melatonin levels in drug-free patients with major depression from the southern hemisphere. Psychoneuroendocrinology 31: 761-768. (Pubitemid 44255602)
7. Carvalho L, Gorenstein C, Moreno R, Pariante C, Markus RP. 2009. Effect of antidepressants on melatonin metabolite in depressed patients. J Psychopharmacol 23(3): 315-321.
8. Cohen J. 1988. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Erlbaum: Hillsdale, NJ.
9. Cook MR, Graham C, Kavet R, Stevens RG, Davis S, Kheifets L. 2000. Morning urinary assessment of nocturnal melatonin secretion in older women. J Pineal Res 28: 41-47. (Pubitemid 30066051)
10. Fava M, Rush AJ, Trivedi MH, et al. 2003. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26: 457-494. (Pubitemid 36583573)
11. Gelenberg AJ. 2010. A review of the current guidelines for depression treatment. J Clin Psychiatry 71(7): e15.
12. Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdr, RW, Potte, WZ. 1988. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry 45: 150-154. (Pubitemid 18052846)
13. Golden RN, Potter WZ. 1986. Neurochemical and neuroendocrine dysregulation in affective disorders. Psychiatr Clin North Am 9(2): 313-327. (Pubitemid 16086975)
14. Gould TD, Manji HK. 2002. Signaling pathways in the pathophysiology of mood disorders. J Psychosom Res 53: 687-697. (Pubitemid 36292448)
15. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. 1998. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res 24(4): 230-238. (Pubitemid 28206444)
16. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
17. Horstmann S, Dose T, Lucae S, et al. 2009. Supressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action. Psychoneuroendocrinology 34(2): 238-248.
18. Huezo-Diaz P, Uher R, Smith R, et al. 2009. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 195(1): 30-38.
19. Klante G, Brinschwitz T, Secci K, Wollnik F, Steinlechner S. 1997. Creatinine is an appropriate reference for urinary sulphatoxymelatonin of laboratory animals and humans. J Pineal Res 23: 191-197. (Pubitemid 127732131)
20. Lam RW, Kennedy SH, Grigoriadis S, et al. 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the management of major depressive disorder in adults III. Pharmacotherapy. J Affect Disord 117(Supl 1): S1-S2.
21. Lucki I, O'Leary OF. 2004. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 65: 11-24.
22. Markus RP, Franco DG, Carvalho LA, Gentil VL, Gorenstein C. 2010. Acute increase in urinary 6-sulfatoxymelatonin after clomipramine, as a predictive measure for emotional improvement. J Psychopharmacol 24: 855-860.
23. Miller HL, Ekstrom RD, Mason GA, Lydiard RB, Golden RN. 2001. Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharmacology 24: 617-623. (Pubitemid 32452209)
24. Okuda A, Suzuki T, Kishi T, et al. 2010. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci 64(3): 268-273.
25. Ortega JE, Fern?ndez-Pastor B, Callado LF, Meana JJ. 2010. In vivo potentiation of reboxetine and citalopram effect on extracellular noradrenaline in rat brain by (2)-adrenoceptor antagonism. Eur Neuropsychopharmcol 20: 813-822.
26. Palazidou E, Papadopoulos A, Ratcliff H, Dawling S, Checkley SA. 1992. Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients. Psychol Med 22: 309-315.
27. Paykel ES. 1999. The Hamilton scales. In Bech, P, Coppen, A (eds). The Hamilton Scales. Springer, New York.
28. Prins J, Denys DA, Westphal KG, et al. 2010. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. Eur J Pharmacol 633(1-3): 55-61.
29. Quera-Salva MA, Lemoine P, Guilleminault C. 2010. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol Clin Exp 25: 222-229.
30. Rush AJ, Fava M, Wisniewski SR, et al. 2004. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25: 119-142. (Pubitemid 38230109)
31. Sanacora G, Zarate CA, Krystal JH, Manji HK. 2008.Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7(5): 426-37. (Pubitemid 351619114)
32. Sapena R, Morin D, Zini R, Tillement JP. 1994. Cyclic AMP and inositol phosphate accumulations in rat brain cortical slices following chronic citalopram or desipramine administration. Drugs Exp Clin Res 20: 93-102. (Pubitemid 24211099)
33. Simmoneaux V, Ribelayga C. 2003. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 55: 325-395. (Pubitemid 36666050)